PAPER Yang Z, Huh SU, Drennan JM, Kathuria H, Martinez JS, Tsuda H, Hall MC, Clemens JC
SEARCH RESULTS
331202 RESULTS
PAPER Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, Bush AI, Finkelstein DI
Ceruloplasmin dysfunction and therapeutic potential for parkinson disease.
Ann Neurol. 2012 Nov 24; PubMed: 23424051PAPER Morales-García JA, Susín C, Alonso-Gil S, Pérez DI, Palomo V, Pérez C, Conde S, Santos A, Gil C, Martínez A, Pérez-Castillo A
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
ACS Chem Neurosci. 2013 Feb 20;4(2):350-60. PubMed: 23421686PAPER Cardenas VA, Tosun D, Chao LL, Fletcher PT, Joshi S, Weiner MW, Schuff N
Voxel-Wise Co-analysis of Macro- and Microstructural Brain Alteration in Mild Cognitive Impairment and Alzheimer's Disease Using Anatomical and Diffusion MRI.
J Neuroimaging. 2013 Feb 19; PubMed: 23421601PAPER Limapichat W, Yu WY, Branigan E, Lester HA, Dougherty DA
Key Binding Interactions for Memantine in the NMDA Receptor.
ACS Chem Neurosci. 2013 Feb 20;4(2):255-60. PubMed: 23421676PAPER Coskuner O, Wise-Scira O, Perry G, Kitahara T
The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.
ACS Chem Neurosci. 2013 Feb 20;4(2):310-20. PubMed: 23421682PAPER More SS, Vartak AP, Vince R
Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.
ACS Chem Neurosci. 2013 Feb 20;4(2):330-8. PubMed: 23421684PAPER Veloso AJ, Dhar D, Chow AM, Zhang B, Tang DW, Ganesh HV, Mikhaylichenko S, Brown IR, Kerman K
sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.
ACS Chem Neurosci. 2013 Feb 20;4(2):339-49. PubMed: 23421685PAPER Seichepine DR, Stamm JM, Daneshvar DH, Riley DO, Baugh CM, Gavett BE, Tripodis Y, Martin B, Chaisson C, McKee AC, Cantu RC, Nowinski CJ, Stern R
Profile of self-reported problems with executive functioning in college and professional football players.
J Neurotrauma. 2013 Feb 19; PubMed: 23421745PAPER Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K
Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in Alzheimer's disease brains.
Neuropathol Appl Neurobiol. 2013 Feb 20; PubMed: 23421764PAPER Li HL, Lu SJ, Sun YM, Guo QH, Sadovnick AD, Wu ZY
The LRRK2 R1628P variant plays a protective role in Han Chinese population with Alzheimer's disease.
CNS Neurosci Ther. 2013 Apr;19(4):207-15. PubMed: 23421816PAPER Liu SY, Wang W, Cai ZY, Yao LF, Chen ZW, Wang CY, Zhao B, Li KS
Polymorphism-116C/G of human X-box-binding protein 1 promoter is associated with risk of Alzheimer's disease.
CNS Neurosci Ther. 2013 Apr;19(4):229-34. PubMed: 23421912PAPER Ritchie CW, Zhinchin G
Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.
Int Psychogeriatr. 2013 Apr;25(4):511-5. PubMed: 23422014PAPER Klein C, Patte-Mensah C, Taleb O, Bourguignon JJ, Schmitt M, Bihel F, Maitre M, Mensah-Nyagan AG
The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction.
Neuropharmacology. 2013 Jul;70:254-60. PubMed: 23422298PAPER Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease.
Nat Commun. 2013;4:1495. PubMed: 23422663Current Filters
No filters selected